Induced pluripotent stem cells and hematological malignancies: A powerful tool for disease modeling and drug development
- PMID: 33142254
- DOI: 10.1016/j.scr.2020.102060
Induced pluripotent stem cells and hematological malignancies: A powerful tool for disease modeling and drug development
Abstract
The derivation of human pluripotent stem cell (iPSC) lines by in vitro reprogramming of somatic cells revolutionized research: iPSCs have been used for disease modeling, drug screening and regenerative medicine for many disorders, especially when combined with cutting-edge genome editing technologies. In hematology, malignant transformation is often a multi-step process, that starts with either germline or acquired genetic alteration, followed by progressive acquisition of mutations combined with the selection of one or more pre-existing clones. iPSCs are an excellent model to study the cooperation between different genetic alterations and to test relevant therapeutic drugs. In this review, we will describe the use of iPSCs for pathophysiological studies and drug testing in inherited and acquired hematological malignancies.
Keywords: Differentiation; Drug screen; Hematological malignancies; iPSCs.
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.
Similar articles
-
Harnessing the Power of Induced Pluripotent Stem Cells and Gene Editing Technology: Therapeutic Implications in Hematological Malignancies.Cells. 2021 Oct 9;10(10):2698. doi: 10.3390/cells10102698. Cells. 2021. PMID: 34685678 Free PMC article. Review.
-
Application of induced pluripotent stem cell technology for the investigation of hematological disorders.Adv Biol Regul. 2019 Jan;71:19-33. doi: 10.1016/j.jbior.2018.10.001. Epub 2018 Oct 10. Adv Biol Regul. 2019. PMID: 30341008 Review.
-
Induced pluripotent stem cell modeling of malignant hematopoiesis.Exp Hematol. 2019 Mar;71:68-76. doi: 10.1016/j.exphem.2019.01.002. Epub 2019 Jan 16. Exp Hematol. 2019. PMID: 30659850 Review.
-
Modeling Hematological Diseases and Cancer With Patient-Specific Induced Pluripotent Stem Cells.Front Immunol. 2018 Sep 28;9:2243. doi: 10.3389/fimmu.2018.02243. eCollection 2018. Front Immunol. 2018. PMID: 30323816 Free PMC article. Review.
-
Modeling of hematologic malignancies by iPS technology.Exp Hematol. 2015 Aug;43(8):654-60. doi: 10.1016/j.exphem.2015.06.006. Epub 2015 Jun 29. Exp Hematol. 2015. PMID: 26135030 Review.
Cited by
-
Harnessing the Power of Induced Pluripotent Stem Cells and Gene Editing Technology: Therapeutic Implications in Hematological Malignancies.Cells. 2021 Oct 9;10(10):2698. doi: 10.3390/cells10102698. Cells. 2021. PMID: 34685678 Free PMC article. Review.
-
Monoallelic KRAS (G13C) mutation triggers dysregulated expansion in induced pluripotent stem cell-derived hematopoietic progenitor cells.Stem Cell Res Ther. 2024 Apr 16;15(1):106. doi: 10.1186/s13287-024-03723-2. Stem Cell Res Ther. 2024. PMID: 38627844 Free PMC article.
-
The Future of Gene Therapy for Transfusion-Dependent Beta-Thalassemia: The Power of the Lentiviral Vector for Genetically Modified Hematopoietic Stem Cells.Front Pharmacol. 2021 Oct 1;12:730873. doi: 10.3389/fphar.2021.730873. eCollection 2021. Front Pharmacol. 2021. PMID: 34658870 Free PMC article. Review.
-
Developing Bottom-Up Induced Pluripotent Stem Cell Derived Solid Tumor Models Using Precision Genome Editing Technologies.CRISPR J. 2022 Aug;5(4):517-535. doi: 10.1089/crispr.2022.0032. CRISPR J. 2022. PMID: 35972367 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources